Recent Amendments to the XOMA Royalty and LAVA Therapeutics Agreement
In a significant development within the biotech sector, XOMA Royalty Corporation (NASDAQ: XOMA) and LAVA Therapeutics N.V. (NASDAQ: LVTX) have reached an agreement to amend the terms of their previously established purchase agreement. This amendment revises the financial components crucial for LAVA shareholders.
Details of the Amendment
The amendment stipulates that LAVA shareholders who choose to tender their shares will receive an initial cash amount of $1.04 per share. This new cash amount is a revision from the prior agreement, which had set the range between $1.16 and $1.24. In addition to this cash compensation, shareholders will also be entitled to a non-transferable contingent value right (CVR). This CVR could yield further cash payments based on net proceeds from LAVA's partnered and unpartnered projects.
Revised Closing Conditions
Another key aspect of the amendment is the adjustment of LAVA's minimum net-cash closing condition, which has been decreased to $24.5 million from the previous $31.5 million. This revision comes as both companies reassess their financial landscapes and expected cash balances. This strategic change allows for increased flexibility during the completion of the acquisition.
Extension of Offer Duration
The offer, which initially had an expiration set for a specific time in October, has now been extended until November. This extension is crucial, allowing more time for potential participants to tender their shares without the need for re-tendering actions. LAVA shareholders have previously mobilized their intent to support the offer, making this extension a strategic decision to secure more robust participation.
Conditions for Closing the Offer
The fulfillment of this offer is contingent upon several conditions, including tendering a significant percentage of LAVA common shares and the adoption of certain resolutions during a shareholder meeting. This meeting will play a pivotal role in the approval of transactions between LAVA and XOMA Royalty.
Extraordinary General Meeting Scheduled
To facilitate shareholder approval, LAVA intends to hold an extraordinary general meeting to address vital matters concerning the partnership with XOMA Royalty. This meeting will occur at a newly determined time, with the venue situated at NautaDutilh N.V. in Amsterdam. This meeting bears importance not only for reviewing the agreement but also for shaping the future strategic direction of both companies.
About XOMA Royalty Corporation
XOMA Royalty plays a crucial role in the biotech industry as a royalty aggregator, supporting emerging companies in realizing their potential to enhance human health. By acquiring future economic rights linked to therapeutic candidates, XOMA Royalty provides non-dilutive funding that companies can utilize for developmental purposes.
About LAVA Therapeutics
LAVA Therapeutics is pioneering the field of biopharmaceuticals with its innovative bispecific gamma delta T cell engagers, showcasing a robust pipeline aimed at treating various cancers. Its collaboration with major pharmaceutical firms highlights the potential of its proprietary technologies to address significant healthcare challenges.
Frequently Asked Questions
What are the main changes in the amended agreement?
The cash amount per share has been revised to $1.04, and the minimum net cash condition has been lowered to $24.5 million.
When is the new date for the extraordinary general meeting?
The extraordinary general meeting is scheduled for November 7, 2025, at 2:00 p.m. Central European Summer Time.
How does the contingent value right (CVR) work?
The CVR entitles shareholders to additional cash payments based on the net proceeds from LAVA's partnered and unpartnered assets.
What is XOMA Royalty's role in the agreement?
XOMA Royalty serves as the acquirer of future economic rights from LAVA, enabling financial support for its ongoing projects.
How can shareholders participate in the tender offer?
Shareholders can participate by tendering their shares according to the amended agreement's terms, now extended until November 12, 2025.
